» Articles » PMID: 34575353

Soluble IL-2R Levels Predict In-Hospital Mortality in COVID-19 Patients with Respiratory Failure

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Sep 28
PMID 34575353
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Acute respiratory distress syndrome is the primary cause of death in patients with coronavirus disease 2019 (COVID-19) pneumonia. Our study aims to determine the association between serum markers and mortality in COVID-19 patients with respiratory failure. This retrospective study was conducted in a tertiary care hospital in South Korea. Forty-nine patients with COVID-19, who required high flow nasal cannulation or mechanical ventilation from February 2020 to April 2021, were included. Demographic and laboratory data were analyzed at baseline and on Day 7 of admission. We found that serum creatinine, troponin, procalcitonin, and soluble interleukin-2 receptor (sIL-2R) at baseline were more elevated in the non-survivor group, but were not associated with mechanical ventilator use on Day 7. Older age, PaO/FiO ratio, lymphocyte and platelet counts, lactate dehydrogenase, IL-6, C-reactive protein, and sIL-2R on Day 7 were significantly associated with mortality. Delta sIL-2R (Day 7-Day 0) per standard deviation was significantly higher in the non-survivor group (adjusted hazard ratio 3.225, 95% confidence interval (CI) 1.151-9.037, = 0.026). Therefore, sIL-2R could predict mortality in COVID-19 patients with respiratory failure. Its sustained elevation suggests a hyper-inflammatory state, and mirrors the severity of COVID-19 in patients with respiratory failure, thereby warranting further attention.

Citing Articles

Identifying and Validating Prognostic Hyper-Inflammatory and Hypo-Inflammatory COVID-19 Clinical Phenotypes Using Machine Learning Methods.

Ji X, Guo Y, Tang L, Gao C J Inflamm Res. 2025; 18:3009-3024.

PMID: 40034687 PMC: 11874972. DOI: 10.2147/JIR.S504028.


Acute onset psychiatric diseases after SARS-CoV-2 virus infection among pediatric patients.

Yang L, Li J, Zhang D Front Neurol. 2024; 15:1445903.

PMID: 39445192 PMC: 11496280. DOI: 10.3389/fneur.2024.1445903.


COVID severity test (CoST sensor)-An electrochemical immunosensing approach to stratify disease severity.

Madhurantakam S, Karnam J, Muthukumar S, Prasad S Bioeng Transl Med. 2023; 8(5):e10566.

PMID: 37693054 PMC: 10486328. DOI: 10.1002/btm2.10566.


Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes.

Dona A, Sanchez J, Palmer J, Synold T, Chiuppesi F, Thomas S J Immunol Sci. 2023; 7(1):9-27.

PMID: 36996290 PMC: 10042490. DOI: 10.29245/2578-3009/2023/1.1241.


Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID.

Dhawan M, Rabaan A, Alwarthan S, Alhajri M, A Halwani M, Alshengeti A Vaccines (Basel). 2023; 11(3).

PMID: 36992283 PMC: 10059134. DOI: 10.3390/vaccines11030699.


References
1.
Sundel R . Kawasaki disease. Rheum Dis Clin North Am. 2014; 41(1):63-73, viii. DOI: 10.1016/j.rdc.2014.09.010. View

2.
Lippi G, Plebani M, Henry B . Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020; 506:145-148. PMC: 7102663. DOI: 10.1016/j.cca.2020.03.022. View

3.
Goshua G, Pine A, Meizlish M, Chang C, Zhang H, Bahel P . Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020; 7(8):e575-e582. PMC: 7326446. DOI: 10.1016/S2352-3026(20)30216-7. View

4.
. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View

5.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View